<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Seroprotection status of hepatitis B and measles vaccines in children with type 1 diabetes mellitus

dc.authorid0000-0003-4930-8447
dc.contributor.authorÖnal, Zerrin
dc.contributor.authorErsen, Atilla
dc.contributor.authorBayramoğlu, Elvan
dc.contributor.authorKazancı Yaroğlu, Selcen
dc.contributor.authorÖnal, Hasan
dc.contributor.authorAdal, Erdal
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:26Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:26Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000384418000002
dc.descriptionPubMed ID: 27658137
dc.description.abstractBackground: Type 1 diabetes mellitus (T1DM) is speculated to have an impaired immunological response to vaccines. This paper aimed to investigate the presence of specific antibodies against hepatitis B virus (HBV) and measles in diabetic children who had been immunized according to the standard national calendar of immunization. Methods: Two hundred and one diabetic children and 140 healthy controls were prospectively evaluated. Antibodies against hepatitis B (anti-HBs) and measles were detected in all individuals who completed the vaccination schedule. We noted onset of T1DM, duration of the disease, diabetes-related autoantibodies and mean HbA(1c) levels. Results: Some 72.6% of diabetics and 82.1% of controls had anti-HBs (+) (p=0.04). We found a reduced efficacy of measles vaccination in anti-HBs (-) diabetic children (p=0.009), even though there was no significant difference between the study and control groups. Onset of the disease was earlier in anti-HBs (-) diabetics than in controls (p=0.038). No difference with respect to other parameters was found. Conclusions: Our data showed a reduced seroprotection rate for HBV vaccination in diabetic children and for measles with anti-HBs (-) diabetics. Larger studies should be encouraged to confirm the vaccine efficacy in diabetic children and to elucidate possible pathogenic mechanisms.
dc.identifier.citationÖnal, Z., Ersen, A., Bayramoğlu, E., Kazancı Yaroğlu, S., Önal, H. ve Adal, E. (2016). Seroprotection status of hepatitis B and measles vaccines in children with type 1 diabetes mellitus. Journal Of Pediatric Endocrinology & Metabolism, 29(9), 1013-1017. https://dx.doi.org/10.1515/jpem-2015-0211
dc.identifier.doi10.1515/jpem-2015-0211
dc.identifier.endpage1017
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.issue9
dc.identifier.scopusqualityQ3
dc.identifier.startpage1013
dc.identifier.urihttps://dx.doi.org/10.1515/jpem-2015-0211
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3271
dc.identifier.volume29
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWalter De Gruyter Gmbh
dc.relation.ispartofJournal Of Pediatric Endocrinology & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChildren
dc.subjectHepatitis B
dc.subjectMeasles
dc.subjectSeroconversion
dc.subjectType 1 Diabetes Mellitus
dc.titleSeroprotection status of hepatitis B and measles vaccines in children with type 1 diabetes mellitus
dc.typeArticle

Files